Fig. 1: Loss of Rb and p53 along with high SKP2 expression in patient-derived OS samples. | Oncogene

Fig. 1: Loss of Rb and p53 along with high SKP2 expression in patient-derived OS samples.

From: Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma

Fig. 1

A Relative mRNA expression levels of TP53, RB1 B and SKP2 C as measured by RNA-seq in 24 PPTC osteosarcoma tumor samples. Relative mRNA expression levels were defined as counts. D Western blot analysis for SKP2, TP53 and RB1 in protein lysates of the same OS samples as above. Three non-tumor mesenchymal cell lines, MSC (mesenchymal stem cells), NDHF (non-dermal human fibroblasts), NHOst (normal human osteoblasts), and 13 OS samples were included. GAPDH was used as a loading control. E Heatmap of relative mRNA expression levels of TP53, RB1 and SKP2 as measured by RNA-seq in PPTC osteosarcoma tumor samples.

Back to article page